Metastatic Colorectal Cancer: Biological Features, Old and New Treatments
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 July 2022) | Viewed by 22541
Special Issue Editors
Interests: Gastrointestinal cancer; Breast cancer; immunohistochemistry; prognostic and predictive markers
Interests: colorectal cancer; immunotherapy; target therapy
Special Issue Information
Colorectal cancer (CRC) is the fourth most common cause of death from cancer in the world, the third most common cancer in men, and the second most common cancer in women. About 25% of patients present with metastatic disease at initial diagnosis and 50% of patients at an early disease stage will develop metastases.
The outcome and the success of therapy for metastatic CRC is related to the resectability of the metastases, the patient’s clinical status, the tumor’s location, and the biomarker profile, which determines the systemic approach to be taken. In an oligometastatic setting, resection or local treatment of metastases using a multimodal approach is a reasonable option.
At present, RAS/BRAF mutational status and tumor location are the gold standards for treatment choice. Emerging data regarding new pathways implicated in resistance to anti-EGFR therapy and the role of immunocheckpoint inhibitors in subsets of tumors need to be further investigated.
Recently, four consensus molecular subtypes of CRC (MSI-immune, Canonical, Metabolic, and Mesenchymal) were identified, each of which is characterized by different biological and clinical features, including metastatic potential, relapse-free survival, and overall survival, and different therapeutic chances of success.
This Special Issue will highlight existing and future potential therapeutic approaches on the basis of our current and emerging knowledge of the biology of metastatic CRC.
Dr. Anna Maria Chiaravalli
Dr. Elena Magni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic colorectal cancer
- molecular profile
- target therapy
- local treatment
- immunotherapy